Table 1.

Current clinical trials in pemphigus.

NCT number	Disease	Interventions	Target	Allocation	Masking	Phase	Status
NCT01930175	PV	VAY736	BAFF-R	Randomized	Double blind	2	Active, not recruiting
NCT01920477	PV	Ofatumumab	CD20	Randomized	Double blind	3	Completed
NCT03334058	PV	ARGX-113	FcRn	Single group	None	2	Recruiting
NCT02704429	PV or PF	PRN1008	BTK	Single group	None	2	Recruiting
NCT03762265	PV or PF	PRN1008	BTK	Randomized	Quadruple blind	3	Recruiting
NCT02383589	PV	Rituximab MMF	CD20 IMPDH	Randomized	Double blind	3	Active, not recruiting
NCT03239470	PV or PF	Poly Tregs	Immune tolerance	Non- randomized	None	1	Recruiting
NCT02828163	PV	PRP	Wound healing	Randomized	Double blind	3	Recruiting
NCT00784589	PV or PF	Rituximab	CD20	Randomized	None	3	Completed
NCT03075904	PV or PF	SYNT001	FcRn	Non-randomized	None	1/2	Completed

PV, pemphigus vulgaris; PF, pemphigus foliaceus; BAFF-R, B cell activating factor of the tumor necrosis factor family receptor; FcRn, neonatal Fc receptor; BTK, Bruton's tyrosine kinase; MMF, mycophenolate mofetil; IMPDH, inosine 5′-monophosphate dehydrogenase; Tregs, regulatory T cells; PRP, Platelet rich plasma.